ArticleJournal of neuroinflammation2022
Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study.
Article in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Risk of Ischemic Stroke After Transient Ischemic Attack in Patients Receiving Comprehensive Versus Noncomprehensive Diagnostic Workup: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Different light color temperatures in the morning on the effectiveness of rehabilitation training in patients with ischemic stroke: a prospective, single-center, randomized controlled clinical trial.Journal of neuroengineering and rehabilitation · 2025Trial
- Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.BMJ (Clinical research ed.) · 2024Trial
- Clinical Utility of Circulating Biomarkers for Diagnosis and Prognosis of Acute Stroke in the Emergency Department: A Narrative Review from Current Evidence to Clinical Implementation.Diagnostics (Basel, Switzerland) · 2026Review
- Age-Related Brain Atrophy Mediates a Composite Outcome of One-Year Ischemic Stroke Recurrence and All-Cause Mortality Through YKL-40-Related Inflammatory Pathways: A Structural Equation Model.Translational stroke research · 2026Article
- The Association Between PIV and Mortality in US Stroke Survivors: A NHANES 1999-2018 Retrospective Cohort Study.Health science reports · 2026Article
- Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review).Molecular medicine reports · 2026Review
- Longitudinal plasma interleukin-6 and post-stroke cognitive outcomes: The Stroke-IMPaCT study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Systemic Inflammation Mediates the Association Between Atrial Fibrillation and Functional Outcomes After Ischemic Stroke.Journal of inflammation research · 2026Article
- Inflammatory profiling for precision neurorehabilitation after traumatic brain injury and stroke: a narrative review.Frontiers in neurology · 2026Review
- Serum interleukin-6 as a neuroinflammatory biomarker across the spectrum of neurological disorders: a large-scale retrospective cohort study of 6,465 individuals.Frontiers in immunology · 2026Observational
- Pan-immune inflammation value and neutrophil-to-albumin ratio predict hemorrhagic transformation after intravenous thrombolysis in acute ischemic stroke: a dual-center cohort study.Frontiers in nutrition · 2026Article
- Beyond Reperfusion: Adjunctive Therapies Targeting Inflammation, Edema, and Blood-Brain Barrier Dysfunction in Ischemic Stroke.Cerebrovascular diseases (Basel, Switzerland) · 2026Review
- Construction of a Risk Prediction Model for Stroke Occurrence in Septic Shock Patients: A Combined Analysis Using LASSO and Multivariate Logistic Regression.International journal of general medicine · 2026Article
- Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement.International journal of molecular sciences · 2025Review
- Inflammatory Burden Index and One-Year Clinical Outcomes in Large Artery Atherosclerosis Ischemic Stroke: A Multicenter Prospective Study.European journal of neurology · 2025Article
- The value of the CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in acute ischemic stroke.Scientific reports · 2025Article
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Chitinase-3 Like-Protein-1 Signature in Neurological Disorders: Emphasis on Stroke.Journal of molecular neuroscience : MN · 2025Review
- Predictive Value of Hyperintense Acute Reperfusion Marker in Transient Ischemic Attacks: Stroke Recurrence and TOAST Classification.Brain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveContribution of individual and combined inflammatory markers in prognosis after stroke was still undefined. We aimed to investigate the association of systemic and local vascular inflammatory markers and recurrent stroke as well as impact on poor functional outcome.
methodsIn this pre-specified substudy of the Third China National Stroke Registry (CNSR-III), 10,472 consecutive acute ischemic stroke or TIA patients with available centralized-measured levels of Interleukin-6 (IL-6), high sensitive C-reactive protein (hsCRP), IL-1 receptor antagonist (IL-1Ra), lipoprotein-associated phospholipase A
resultsThere were 1026 (9.8%) and 2395 (23.4%) patients with recurrent stroke and poor functional outcome within 1 year. The highest quartiles of IL-6 (adjusted HR, 1.36; 95% CI 1.13-1.64; P = 0.001), hsCRP (adjusted HR, 1.41; 95% CI 1.17-1.69; P = 0.0003) and YKL-40 (adjusted HR, 1.28; 95% CI 1.06-1.56; P = 0.01) were associated with increased risk of recurrent stroke; and the highest quartiles of IL-6 (adjusted OR 1.93; 95% CI 1.64-2.27; P < 0.0001), IL-1Ra (adjusted OR 1.60; 95% CI 1.37-1.87; P < 0.0001), hsCRP (adjusted OR 1.60; 95% CI 1.37-1.86; P < 0.0001) and YKL-40 (adjusted OR 1.21; 95% CI 1.03-1.42; P = 0.02) were correlated with increased risk of poor functional outcome. In the multivariate stepwise regression analysis including all markers with backward selection, elevated levels of IL-6 or YKL-40 were associated with recurrent stroke (IL6: OR, 1.34; 95% CI 1.19-1.52; P < 0.0001; YKL-40: OR, 1.01; 95% CI 1.01-1.03; P = 0.004) and poor functional outcome (IL6: OR, 1.68; 95% CI 1.46-1.93; P < 0.0001; YKL-40: OR, 1.02; 95% CI 1.01-1.03; P = 0.0001). Adding IL-6 and YKL-40 significantly increased the area under the receiver operating characteristic curves for the prediction models of Essen Stroke Risk Score (0.03, P < 0.0001) and Totaled Health Risks in Vascular Events Score (0.07, P < 0.0001), and yielded continuous net reclassification improvement (19.0%, P < 0.0001; 33.0, P < 0.0001).
conclusionsIn the patients with ischemic stroke or TIA, IL-6 and YKL-40 were independently associated with recurrent stroke and poor functional outcome, and improved risk classification of clinical risk algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.